(Q42859163)

8 November 2017

0 references

Attainment of Canadian and European guidelines' lipid targets with atorvastatin plus ezetimibe vs. doubling the dose of atorvastatin (English)

1 reference

8 November 2017

Attainment of Canadian and European guidelines’ lipid targets with atorvastatin plus ezetimibe vs. doubling the dose of atorvastatin (English)

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02530.X

2 August 2024

author name string

L. A. Leiter

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20946261

2 August 2024

H. Bays

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20946261

2 August 2024

S. Conard

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20946261

2 August 2024

J. Lin

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20946261

2 August 2024

M. E. Hanson

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20946261

2 August 2024

A. Shah

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20946261

2 August 2024

A. M. Tershakovec

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20946261

2 August 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20946261

2 August 2024

publication date

14 October 2010

1 reference

full work available at URL

8 November 2017

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1742-1241.2010.02530.x

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02530.X

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1742-1241.2010.02530.x/fullpdf

2 August 2024

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02530.X

International Journal of Clinical Practice

2 August 2024

published in

1 reference

8 November 2017

volume

64

1 reference

8 November 2017

issue

13

1 reference

8 November 2017

page(s)

1765-1772

1 reference

2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations

8 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02530.X

European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by rep

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02530.X

Canadian Cardiovascular Society position statement--recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02530.X

Efficacy and tolerability of ezetimibe 10 mg/day coadministered with statins in patients with primary hypercholesterolemia who do not achieve target LDL-C while on statin monotherapy: A Canadian, multicentre, prospective study--the Ezetrol Add-On St

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2010.02530.X

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02530.X

European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice ...

2 August 2024

2

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02530.X

Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis

2 August 2024

4

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02530.X

Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association

2 August 2024

6

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02530.X

Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease

2 August 2024

7

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02530.X

Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease

2 August 2024

8

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02530.X

AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update

2 August 2024

10

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02530.X

Cholesterol goal attainment in patients with coronary heart disease and elevated coronary risk: results of the Hong Kong hospital audit study

2 August 2024

11

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02530.X

Determinants of compliance with statin therapy and low-density lipoprotein cholesterol goal attainment in a managed care population

2 August 2024

12

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02530.X

The low-density lipoprotein cholesterol-lowering effect of pravastatin and factors associated with achieving targeted low-density lipoprotein levels in an African-American population

2 August 2024

14

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02530.X

Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel.

2 August 2024

15

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02530.X

Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial

2 August 2024

16

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02530.X

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

2 August 2024

17

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02530.X

Effect of fluvastatin on ischaemia following acute myocardial infarction: a randomized trial

2 August 2024

18

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02530.X

A review of high-dose statin therapy: targeting cholesterol and inflammation in atherosclerosis

2 August 2024

19

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02530.X

High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial

2 August 2024

20

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02530.X

Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial

2 August 2024

21

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02530.X

Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial

2 August 2024

22

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02530.X

Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial

2 August 2024

23

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02530.X

Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia

2 August 2024

24

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02530.X

Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia

2 August 2024

25

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02530.X

Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial

2 August 2024

26

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02530.X

A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial

2 August 2024

28

1 reference

https://api.crossref.org/works/10.1111/J.1742-1241.2010.02530.X

2 August 2024

Identifiers

1 reference

8 November 2017

1 reference